Patents by Inventor Yogita Krishnamachari

Yogita Krishnamachari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF AND METHODS OF USE THEREOF
    Publication number: 20230365692
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
    Type: Application
    Filed: September 23, 2021
    Publication date: November 16, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Yogita KRISHNAMACHARI, Sachin MITTAL, Sahil S. SANGANI, William P. FORREST, Jr., Yongchao SU, Xi ZHAO, Katelyn Jean SMITH
  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230321234
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti- PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: March 10, 2023
    Publication date: October 12, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, Jr., Yogita Krishnamachari
  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230263887
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: March 10, 2023
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, Jr., Yogita Krishnamachari
  • Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
    Patent number: 11633476
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 25, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, Yogita Krishnamachari
  • Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
    Publication number: 20220089738
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yogita Krishnamachari, Sachin Mittal, Sahil S. Sangani, William P. Forrest, JR., Yongchao Su, Xi Zhao
  • CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
    Publication number: 20220002410
    Abstract: The present invention provides co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
    Type: Application
    Filed: November 6, 2019
    Publication date: January 6, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Valentyn Antochshuk, Preeti G. Desai, Yogita Krishnamachari, Sahil S. Sangani
  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210380694
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-250 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof, a buffer, a stabilizer, a surfactant, and an antioxidant in the amounts specified herein. In particular embodiments, the anti-PD-1 antibody is pembrolizumab. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: November 6, 2019
    Publication date: December 9, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: William P. Forrest, Jr., Chakravarthy Nachu Narasimhan, Yogita Krishnamachari
  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200147213
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: May 1, 2018
    Publication date: May 14, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, JR., Yogita Krishnamachari
  • Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
    Patent number: 10561654
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: February 18, 2020
    Assignee: Array BioPharma Inc.
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
    Patent number: 10258622
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methyl-sulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 16, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20190054086
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2- yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Application
    Filed: March 14, 2018
    Publication date: February 21, 2019
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
    Patent number: 9763941
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methyl -sulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 19, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20170202837
    Abstract: This invention relates to solid oral pharmaceutical formulations or(S)-methyl ((4(4-(3-(5-chtoro-2-fluoro-3-(methyl-sutfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Application
    Filed: March 7, 2017
    Publication date: July 20, 2017
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • Biodegradable particulate formulations
    Patent number: 9572894
    Abstract: The present invention provides three-component compositions comprising microparticles, a tumor antigen, a first immune adjuvant, and a second immune adjuvant. Also provided are chemo-immunotherapeutic compositions comprising microparticles, a chemotherapeutic agent, and an immune adjuvant.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: February 21, 2017
    Assignee: The University of Iowa Research Foundation
    Inventors: Aliasger K. Salem, Sean M. Geary, George J. Weiner, Caitlin Lemke, Yogita Krishnamachari
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20160279129
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methyl sulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • BIODEGRADABLE PARTICULATE FORMULATIONS
    Publication number: 20140127253
    Abstract: The present invention provides three-component compositions comprising microparticles, a tumor antigen, a first immune adjuvant, and a second immune adjuvant. Also provided are chemo-immunotherapeutic compositions comprising microparticles, a chemotherapeutic agent, and an immune adjuvant.
    Type: Application
    Filed: October 18, 2011
    Publication date: May 8, 2014
    Applicant: University of Iowa Research Foundation
    Inventors: Aliasger K. Salem, Sean M. Geary, George J. Weiner, Caitlin Lemke, Yogita Krishnamachari
  • Self-Assembly of a Cell-Microparticle Hybrid
    Publication number: 20100190257
    Abstract: The present invention provides a fabrication method for the formation of a cell-microparticle hybrid. A biotin-avidin binding system also employs the use of a biodegradable polymer and any cell type that self-assemble to form a hybrid system.
    Type: Application
    Filed: January 25, 2009
    Publication date: July 29, 2010
    Inventors: Aliasger K. Salem, Yogita Krishnamachari